Ascendis Pharma A/S (ASND) company profile
Close on Nov 13, 2026Market cap $17.07BP/E 22.4Yield –
About Ascendis Pharma A/S
Pharmaceutical Preparations, SIC 2834
Ascendis Pharma A/S is a biopharmaceutical company that develops therapies using its proprietary TransCon technology platform to address unmet medical needs. The company focuses primarily on endocrinology rare diseases and oncology, while pursuing partnerships in metabolic diseases, cardiovascular diseases, and ophthalmology. Its commercial portfolio includes YORVIPATH for the treatment of hypoparathyroidism in adults and SKYTROFA for growth hormone deficiency in pediatric and adult patients. Ascendis Pharma provides these prescription medicines to patients and healthcare providers through integrated commercial organizations, specialty pharmacy networks, and regional collaboration partners.
The company is headquartered in Hellerup, Denmark, with registered and executive offices located there. Its commercial footprint spans the United States, several European countries including Germany, Austria, Spain, and Luxembourg, as well as Japan and China through strategic partners. In addition, the company maintains distribution and licensing agreements covering more than 75 countries internationally.
Summary of the business section of Ascendis Pharma A/S's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Ascendis Pharma A/S
- Founded
- 2006
- Headquarters
- Hellerup, Denmark
- Address
- Tuborg Boulevard 12
- Phone
- (457) 022-2244
- Website
- ascendispharma.com
- Employees
- 879, Dec 31, 2023
- Industry
- Pharmaceutical Preparations
- Incorporated in
- G7
- Fiscal year ends
- December 31
- Auditor
- Deloitte Statsautoriseret Revisionspartnerselskab, Copenhagen, Denmark
Stock & identifiers
- Ticker
- ASND
- Exchange
- Nasdaq
- IPO date
- Jan 28, 2015
- Shares outstanding
- 62M, Dec 31, 2025
- Filer category
- Large accelerated filer
- SEC CIK
- 1612042
- CUSIP
- K08588103
- FIGI
- BBG007R7VNC1
- Share class FIGI
- BBG007R7VP72
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Mads Bodenhoff | SVP & PAO | 0 |
| Scott Thomas Smith | EVP & Chief Financial Officer | 4,367 |
| Flemming Steen Jensen | See Remarks | 0 |
| Kennett Sprogoe | See Remarks | 19,570 |
| Aimee Shu | EVP & Chief Medical Officer | 0 |
| Jay Donovan Wu | EVP & President US Market | 1,068 |
| Michael Wolff Jensen | EVP, Chief Legal Officer | – |
| Anni Lotte Kirstine Sonderbjerg Pedersen | EVP & Chief Admin Officer | 19,460 |
| Jean Jacques Bienaime | Director | 2,900 |
| Lars Holtug | Director | 4,000 |
| Albert Cha | Director | 3,730 |
| Siham Imani | Director | 2,317 |
| Jan Moller Mikkelsen | Director | 453,403 |
| William Fairey | Director | 2,117 |
| Lisa Morrison | Director | 1,572 |
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Jan 28, 2015
- Offer price
- $18.00
- Securities offered
- 6,000,000
- Gross proceeds
- $108.00M
- Exchange
- Nasdaq
- Lock-up ends (est.)
- Jul 27, 2015
“The initial public offering price is $18.00 per ADS.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“As of December 31, 2023, we had 879 employees worldwide, with key facilities in Denmark, Germany, and the United States.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Jan 28, 2015 | IPO | Initial public offering priced (424B4 prospectus) |
| Jan 26, 2015 | Listing | Registration of securities on an exchange (Form 8-A) |
See a number that looks wrong?